Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jul 16;13(7):8762–8774. doi: 10.3390/ijms13078762

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

The functional relevance of miR-125b and its targets in HCCs. (A) Results of the CCK-8 assay for the proliferation of HepG2 cells after their transfection with either specific siRNAs targeting Mcl-1 (si_Mcl-1) and IL6R (si_IL6R) or the scrambled oligonucleotide at different culture durations. (B) The cell-cycle analysis of HepG2 cells treated with either specific siRNAs targeting Mcl-1 (si_Mcl-1) and IL6R (si_IL6R) or with the scrambled oligonucleotide and cultured for 24 h after cell transfection. (C) HepG2 cells were treated under the “rescue” condition; this panel illustrates the immunoblotting results of Mcl-1 and IL6R in extracts from HepG2 cells that were either transfected with the miR-125b mimic or the scrambled oligonucleotide for 24 h and then subsequently treated for an additional 48 h with either pcDNA-Mcl-1, pcDNA-IL6R, or pcDNA-empty. (D) The cell cycle analysis of HepG2 cells treated under the “rescue” condition described in the previous panel.

The functional relevance of miR-125b and its targets in HCCs. (A) Results of the CCK-8 assay for the proliferation of HepG2 cells after their transfection with either specific siRNAs targeting Mcl-1 (si_Mcl-1) and IL6R (si_IL6R) or the scrambled oligonucleotide at different culture durations. (B) The cell-cycle analysis of HepG2 cells treated with either specific siRNAs targeting Mcl-1 (si_Mcl-1) and IL6R (si_IL6R) or with the scrambled oligonucleotide and cultured for 24 h after cell transfection. (C) HepG2 cells were treated under the “rescue” condition; this panel illustrates the immunoblotting results of Mcl-1 and IL6R in extracts from HepG2 cells that were either transfected with the miR-125b mimic or the scrambled oligonucleotide for 24 h and then subsequently treated for an additional 48 h with either pcDNA-Mcl-1, pcDNA-IL6R, or pcDNA-empty. (D) The cell cycle analysis of HepG2 cells treated under the “rescue” condition described in the previous panel.